Literature DB >> 26218767

A 'One Stop' Prostate Clinic for rural and remote men: a report on the first 200 patients.

Steve P McCombie1,2,3, Cynthia Hawks1,2, Jon D Emery4,5,6, Dickon Hayne1,2,3,7.   

Abstract

OBJECTIVE: To report on the structure and outcomes of a new 'One Stop' Prostate Clinic (OSPC) designed specifically for rural and remote men. PATIENTS AND METHODS: Prospective cohort study of the first 200 rural or remote men to access a new OSPC at a public tertiary-level hospital in Western Australia between August 2011 and August 2014. Men attended for urological assessment, and proceeded to same-day transrectal ultrasonography-guided prostate biopsies, if appropriate. Referral criteria were either two abnormal age-related prostate-specific antigen (PSA) levels in the absence of urinary tract infection (UTI), or an abnormal digital rectal examination (DRE) regardless of PSA level.
RESULTS: The median (range) distance travelled was 1545 (56-3229) km and median (range) time from referral to assessment was 33 (2-165) days. The median (range) age was 62 (38-85) years, PSA level was 6.7 (0.5-360) ng/mL and 39% (78/200) had a suspicious DRE. In all, 92% (184/200) of men proceeded to prostate biopsies, and 60% (111/184) of these men were diagnosed with prostate cancer. Our complication rate was 3.5% (6/172). Radical prostatectomy (46/111), active surveillance (28/111) and external beam radiation therapy (26/111) were the commonest subsequent treatment methods. A $1045 (Australian dollars) cost-saving per person was estimated based on the reduced need for travel with the OSPC model.
CONCLUSION: The OSPC is an effective and efficient model for assessing men suspected of having prostate cancer living in rural and remote areas of Western Australia, and this model may be applicable to other areas.
© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  health care delivery; prostate cancer; rapid access; rural health

Mesh:

Year:  2015        PMID: 26218767     DOI: 10.1111/bju.13100

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  General practitioner referrals to one-stop clinics for symptoms that could be indicative of cancer: a systematic review of use and clinical outcomes.

Authors:  Claire Friedemann Smith; Alice Tompson; Gea A Holtman; Clare Bankhead; Fergus Gleeson; Daniel Lasserson; Brian D Nicholson
Journal:  Fam Pract       Date:  2019-05-23       Impact factor: 2.267

2.  Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.

Authors:  Rasa Ruseckaite; Fanny Sampurno; Jeremy Millar; Mark Frydenberg; Sue Evans
Journal:  BMC Urol       Date:  2016-09-02       Impact factor: 2.264

3.  The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia.

Authors:  Jon D Emery; Victoria Gray; Fiona M Walter; Shelley Cheetham; Emma J Croager; Terry Slevin; Christobel Saunders; Timothy Threlfall; Kirsten Auret; Anna K Nowak; Elizabeth Geelhoed; Max Bulsara; C D'Arcy J Holman
Journal:  Br J Cancer       Date:  2017-09-19       Impact factor: 7.640

Review 4.  Transrectal ultrasound biopsy of the prostate: does it still have a role in prostate cancer diagnosis?

Authors:  Andrew Moe; Dickon Hayne
Journal:  Transl Androl Urol       Date:  2020-12

5.  'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).

Authors:  Dickon Hayne; Jeremy Grummet; David Espinoza; Steve P McCombie; Venu Chalasani; Kate S Ford; Mark Frydenberg; Peter Gilling; Barbara Gordon; Cynthia Hawks; Alex Konstantatos; Andrew J Martin; Anthony Nixon; Colin O'Brien; Manish I Patel; Shomik Sengupta; Shekib Shahbaz; Shalini Subramaniam; Scott Williams; Henry H Woo; Martin R Stockler; Ian D Davis; Nick Buchan
Journal:  BJU Int       Date:  2021-07-30       Impact factor: 5.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.